Spectrum sees 2019 SG&A costs down 30% vs. 2018

The company states: “Assuming the previously announced divestiture transaction closes in March, we expect 2019 SG&A costs to decrease by approximately 30% relative to 2018. We expect 2019 R&D costs to increase nominally as reduced spending on the legacy assets is offset by the increased spending on pre-commercial supply and tech transfer activities for ROLONTIS and poziotinib. With the increase of cash from the sale of our commercial assets, we expect our cash balance to be sufficient to fund operations for at least three years.”
https://thefly.com/landingPageNews.php?id=2872599